Journal Article

Refractory Coccidioidomycosis Treated with Posaconazole

Gregory M. Anstead, Gavin Corcoran, James Lewis, Deborah Berg and John R. Graybill

in Clinical Infectious Diseases

Published on behalf of Infectious Diseases Society of America

Volume 40, issue 12, pages 1770-1776
Published in print June 2005 | ISSN: 1058-4838
Published online June 2005 | e-ISSN: 1537-6591 | DOI: http://dx.doi.org/10.1086/430303
Refractory Coccidioidomycosis Treated with Posaconazole

More Like This

Show all results sharing these subjects:

  • Infectious Diseases
  • Immunology
  • Public Health and Epidemiology
  • Microbiology

GO

Show Summary Details

Preview

Background. Disseminated coccidioidomycosis (which is caused by the endemic fungi of the genusCoccidioides) can be a life-threatening systemic fungal infection. Although conventional antifungal therapies have activity againstCoccidioides, the disease can be refractory to standard therapies. Drug-associated toxicities also may limit the clinical utility of the standard antifungal drugs. In addition, relapses in patients with disseminated coccidioidomycosis are common, making long-term management of this disease challenging.

Methods. We report the outcomes of 6 patients with coccidioidomycosis who were treated with posaconazole salvage therapy after treatment with conventional antifungal therapies failed to produce sustained clinical improvement. Patients were administered posaconazole oral suspension 800 mg/day in divided doses as part of an open-label clinical trial. A modified version of the Mycoses Study GroupCoccidioides scoring system was used to evaluate the burden of disease. Posaconazole therapy resulted in rapid clinical improvements in the signs and symptoms of coccidioidomycosis.

Results. At the end of therapy, 5 of 6 patients had successful outcomes. Posaconazole was well tolerated despite long-term administration (1–2 years), and 2 patients continued to receive posaconazole maintenance therapy at the time of writing

Conclusions. The successful outcomes observed in this case series suggest that posaconazole is an effective therapy for coccidioidomycosis.

Journal Article.  4019 words.  Illustrated.

Subjects: Infectious Diseases ; Immunology ; Public Health and Epidemiology ; Microbiology

Full text: subscription required

How to subscribe Recommend to my Librarian

Users without a subscription are not able to see the full content. Please, subscribe or login to access all content.